MTOR and hyperlipidemia: Mammalian target of rapamycin (mTOR) inhibitors have attained significant attention in the field of oncology and exhibit a wide range of toxic effects like headache, mucositis, rashes, and metabolic toxicities including hyperglycemia, hyperlipidemia, and hypophosphatemia.